Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study)
Zwicker J, Schlechter B, Stopa J, Liebman H, Aggarwal A, Caughey T, Bauer K, Kuemmerle N, Wong E, Wun T, Mclaughlin M, Puligandla M, Neuberg D, Furie B, Flaumenhaft R. Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study). Blood 2018, 132: 985. DOI: 10.1182/blood-2018-99-114946.Peer-Reviewed Original ResearchVenous thromboembolismDay 56Major hemorrhageAdvanced cancerAntithrombotic efficacyCancer patientsHigh riskThrombus formationD-dimer plasma concentrationIncidence of VTEPlasma D-dimer levelsNon-small cell lungPhase II clinical trialPlatelet-dependent thrombin generationPrevent Venous ThromboembolismPhase II studySecond-line chemotherapySymptomatic pulmonary embolismD-dimer levelsLower extremity DVTPhase II trialMonths of initiationLower extremity ultrasoundSoluble P-selectinInitial human studies